Pilot Study on Non-Invasive Vagus Nerve Stimulation in IBD Remission
The VIBRANT-IBD study explores a novel therapeutic approach for managing inflammatory bowel disease (IBD) through non-invasive vagus nerve stimulation. Successful outcomes could reshape treatment paradigms and influence portfolio strategies for companies focused on IBD therapies.
Phase III
Crohn's disease therapies
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The VIBRANT-IBD study explores a novel therapeutic approach for managing inflammatory bowel disease (IBD) through non-invasive vagus nerve stimulation. Successful outcomes could reshape treatment paradigms and influence portfolio strategies for companies focused on IBD therapies.
Why it matters
The VIBRANT-IBD study explores a novel therapeutic approach for managing inflammatory bowel disease (IBD) through non-invasive vagus nerve stimulation. Successful outcomes could reshape treatment paradigms and influence portfolio strategies for companies focused on IBD therapies.
What changed
Trial Update
Analysis
The VIBRANT-IBD study is assessing the feasibility of non-invasive vagus nerve stimulation in IBD patients in remission.
The VIBRANT-IBD study explores a novel therapeutic approach for managing inflammatory bowel disease (IBD) through non-invasive vagus nerve stimulation. Successful outcomes could reshape treatment paradigms and influence portfolio strategies for companies focused on IBD therapies.
Monitor results from the MRI assessments and psychological questionnaires, as well as participant feedback on the intervention.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.